C4 Therapeutics (CCCC) awards 240,000 RSUs to Chief Scientific Officer

Rhea-AI Filing Summary

C4 Therapeutics, Inc. reported equity compensation and related share movements for Chief Scientific Officer Paige Mahaney. On February 13, 2026, Mahaney received a grant of 240,000 restricted stock units (RSUs). Of these, 120,000 RSUs will vest in three equal annual installments starting on February 13, 2027, and 120,000 RSUs will vest in full on February 13, 2029, with the latter portion subject to performance milestones.

On February 14, 2026, Mahaney acquired 7,050 shares of common stock upon vesting of a previously disclosed RSU grant, and 2,446 shares were withheld by the company to cover tax obligations, which the filing states does not represent a sale. After these transactions, Mahaney directly owned 336,910 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahaney Paige

(Last) (First) (Middle)

C4 THERAPEUTICS, INC.

490 ARSENAL WAY, SUITE 120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A		240,000(1)	A	$0	339,356	D
Common Stock	02/14/2026		M(2)	V	7,050	A	$0	339,356	D
Common Stock	02/14/2026		F(3)		2,446	D	$1.89	336,910	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.

2. Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of RSUs. The grant of RSUs was initially reported in Table I of the Forms 4 filed by the Reporting Person on February 18, 2025.

3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did C4 Therapeutics (CCCC) grant to Paige Mahaney?

C4 Therapeutics granted Paige Mahaney 240,000 RSUs. Half, or 120,000 RSUs, vest in three equal annual installments from February 13, 2027, and the remaining 120,000 RSUs vest in full on February 13, 2029 subject to performance milestones.

How do the new RSUs for C4 Therapeutics (CCCC) Chief Scientific Officer vest?

The 240,000 RSUs vest in two tranches. 120,000 RSUs vest in three equal annual installments starting February 13, 2027. The other 120,000 RSUs vest entirely on February 13, 2029, contingent on achieving specified performance milestones.

What share transactions did Paige Mahaney report for C4 Therapeutics (CCCC)?

Mahaney acquired 7,050 shares of common stock on February 14, 2026 from the vesting of a prior RSU grant. On the same date, 2,446 shares were withheld by the company to satisfy tax obligations related to that vesting.

Did Paige Mahaney sell any C4 Therapeutics (CCCC) shares in this Form 4?

The filing states 2,446 shares were withheld to satisfy tax withholding obligations upon RSU vesting and clarifies this does not represent a sale by Paige Mahaney. The transaction is characterized as tax-related share withholding.

How many C4 Therapeutics (CCCC) shares does Paige Mahaney own after these transactions?

After the reported transactions, Paige Mahaney directly owned 336,910 shares of C4 Therapeutics common stock. This total reflects the RSU-related share acquisition and the tax withholding share reduction recorded in the Form 4.

What prior award is linked to the 7,050 C4 Therapeutics (CCCC) shares acquired?

The 7,050 shares acquired on February 14, 2026 came from the vesting of a previously disclosed RSU grant. That original RSU award was first reported in a Form 4 filed by Paige Mahaney on February 18, 2025.